Q BIOMED DRUG DEVELOPMENT PARTNER TO ATTEND EANM 2016 in BARCELONA, SPAIN October 15-19 2016

Q BIOMED DRUG DEVELOPMENT PARTNER TO ATTEND EANM 2016 in BARCELONA, SPAIN October 15-19 2016 Annual European Association Nuclear Medicine Congress Most Valuable Meeting World Wide NEW YORK, October 18, 2016 — Q BioMed Inc. (OTCQB: QBIO), drug development partner will attend the European Association of Nuclear Medicine (EANM) meeting in Barcelona, Spain. With more […]

Read More

Q BIOMED PARTNER MANNIN RESEARCH EXECUTIVES ATTENDING OIS@AAO 2016 & AAO

Q BIOMED PARTNER MANNIN RESEARCH EXECUTIVES ATTENDING OIS@AAO 2016 & AAO Ophthalmology Summits Attract Broad Range of Industry Professionals NEW YORK, October 13, 2016 — Q BioMed Inc. (OTCQB: QBIO), technology partner Mannin Research Inc will participate at the the Ophthalmology Innovation Summit  and the American Academy of Ophthalmology Annual Meeting in Chicago IL. Mannin […]

Read More

Q BIOMED CLOSES LICENSING AGREEMENT FOR FDA APPROVED DRUG

Q BIOMED CLOSES LICENSING AGREEMENT FOR FDA APPROVED DRUG       Cancer palliation drug expected to start generating revenue in less than 12 months NEW YORK, September 7, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to announce the closing of an exclusive license and option agreement for a FDA approved […]

Read More

Q BIOMED PROVIDES UPDATE ON CORPORATE DEVELOPMENTS

Q BIOMED PROVIDES UPDATE ON CORPORATE DEVELOPMENTS Media Alert: CEO Interviewed on ‘The Stock Radio’ NEW YORK, September 1, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to report on its asset acquisition and an update on corporate development. While the summer months have been typically slow, we have made […]

Read More

Q BIOMED INC. ADVISOR AND MANNIN RESEARCH INC CSO DR SUSAN QUAGGIN ELEQUENTLY DISCUSSES GLAUCOMA AND MAN-01 WITH EYE ON VISION RADIO

Media Alert – Radio and Podcast Interview with Eye on Vision WYPL-FM 89.3 NEW YORK, July 14 2016 — Q BioMed Inc. (OTCQB: QBIO), partner Mannin Research Inc. CSO Dr. Susan Quaggin discusses glaucoma, treatment options, and her novel findings on the relationship between Tie2/TEK signaling, Schelmm’s Canal and glaucoma with Eye on Vision. In […]

Read More

NEW SNN Interview with Q BioMed Inc. CEO Mr. Denis Corin at the Marcum Microcap Conference June 2016

In this video interview, Mr. Corin and SNN host Robert Kraft discuss the following topics: Overview of Q BioMed Inc. Update since our last interview (Click here) Discusses recent news and catalysts New potential FDA approved Drug License Deal What differentiates QBIO from the competition Communicating the stories of projects under development Near-term goals and […]

Read More

Q BIOMED INC. REPORTS ON CURRENT AND NEW POTENTIAL ASSETS

New Near Term Revenue Asset Deal Pending and MAN-01 Drug Candidate Optimization and Selection Progressing on Schedule NEW YORK, June 1, 2016 — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to report on new potential asset license/acquisition and an update on Man 01 development. We are pleased to announce that we […]

Read More
Social media & sharing icons powered by UltimatelySocial